Your dog was diagnosed with Prostatic Carcinoma. Uncommon but highly aggressive. Occurs in BOTH castrated and intact male dogs (unlike benign prostatic hyperplasia which is only intact). Some evidence that neutered dogs may be at equal or higher risk. Typically presents with dysuria, haematuria, or hindlimb stiffness from sublumbar LN or skeletal metastasis. Compare 3 treatment options for dogs including Piroxicam (NSAID) Monotherapy, Radiation Therapy (IMRT/Palliative), Palliation (Stenting + Pain Management) — with survival times, costs, and what to expect during treatment.
Pet Cancer Options — Prostatic Carcinoma
Canine Oncology Treatment Guide
Prostatic Carcinoma
Epithelial
About This Cancer
Prostatic carcinoma is an aggressive cancer arising from the glandular or transitional cells of the prostate gland. An important distinction from benign prostatic enlargement (which affects only intact male dogs) is that prostatic cancer occurs in both castrated and intact dogs — in fact, some evidence suggests neutered dogs may be at equal or even higher risk, though this relationship is still being studied. The tumour is locally invasive, often extending into the urethra and trigone of the bladder, and has a high rate of spread to the sublumbar lymph nodes and to bone — particularly the lumbar spine and pelvis, which can cause hind-limb stiffness or pain. It typically presents with difficulty urinating, bloody urine, or straining to defecate. The prognosis is generally poor, as the cancer is usually advanced at diagnosis and complete surgical removal is rarely feasible. Treatment focuses on pain management, maintaining urinary function, and slowing progression.
No universally adopted staging system
Staged by local extent, lymph node, skeletal, and distant metastasis
Prognostic Factors(2)
Minimum Workup(7 steps)
Median Survival Time Comparison
How long the average patient survives with each treatment
Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.
Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.